A new Optum report highlighting upcoming medications in the drug pipeline is meant as a heads-up for payers as they track developments with a couple of therapies for Alzheimer’s disease – lecanemab and donanemab.
Optum to payers: Two new Azheimer’s drugs are in the pipeline
